Download Our Catalog - Cancer Prevention Fellowship Program

NCI-FDA Joint Training in
Cancer Prevention
Cancer Prevention Fellows are eligible to
participate in the NCI-FDA joint training in cancer
prevention initiative, under the auspices of the
Interagency Oncology Task Force (IOTF) Track 4.
This component of the CPFP provides training in
cancer prevention and in the development and
approval processes of drugs, biologic agents,
devices, or nutritional products. The program’s
interdisciplinary training will enable scientists to
more rapidly move novel chemopreventive agents
and early detection methods from the laboratory to
the community.
Background and Rationale. In 2003, the NCI
Director and the FDA Commissioner joined
forces to more rapidly identify effective cancer
preventive agents and cancer treatments, thereby
accelerating the process of introducing new agents
into the clinic. Arising from
this joint commitment
was an initiative to train
postdoctoral scientists
and clinicians in research
in cancer prevention,
drug development,
and regulatory review.
Research training
opportunities exist in
“The CPFP is a fantastic program, several centers at the FDA.
offering unparalleled research
and training opportunities in a
genuinely supportive environment.
This fellowship has encouraged
me to collaborate with experts
across NCI and NIH, allowing
me to refine my research
interests and develop my skills
as an independent scientist.”
The NCI-FDA joint training in cancer prevention
initiative will provide the opportunity for fellows
to participate in all the activities of the CPFP at
the NCI and in research and product development
and regulatory review at the FDA. Combining
training in public health, cancer prevention, and
product development and regulatory research will
allow individuals to develop expertise across three
disciplines.
Research Opportunities. General categories of
research topics include:
••
Cancer risk of drug, device, and
gene therapy products
••
Cellular substrates in vaccine development
••
Clinical trial design and analytic methodology
••
Development and selection of biomarkers
and clinical endpoints in clinical trials
••
Development of chemopreventive agents
••
Genetic toxicology and cancer prevention
••
Genomic and proteomic approaches
to early detection of cancer
••
Molecular and genetic approaches
in product development
••
Nutrition science and policy
••
Screening and early detection
••
Tobacco control and prevention
••
Vaccination and cancer prevention
Further information is available at
http://iotftraining.nci.nih.gov.
Jada Hamilton, Ph.D., M.P. H.,
Fellow Almuna, Cancer
Prevention Fellowship Program
8 National Cancer Institute